Xencor, Inc. (NASDAQ:XNCR) Shares Purchased by RTW Investments LP

RTW Investments LP boosted its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 317.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,402,883 shares of the biopharmaceutical company's stock after acquiring an additional 1,827,883 shares during the period. RTW Investments LP owned about 3.43% of Xencor worth $55,218,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Xencor by 5.5% in the fourth quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock valued at $184,239,000 after acquiring an additional 418,040 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Xencor by 2.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company's stock valued at $92,758,000 after acquiring an additional 107,350 shares during the period. TCG Crossover Management LLC boosted its holdings in shares of Xencor by 1.0% in the fourth quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company's stock valued at $56,350,000 after acquiring an additional 25,000 shares during the period. BVF Inc. IL boosted its holdings in shares of Xencor by 169.3% in the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company's stock valued at $52,596,000 after acquiring an additional 1,438,760 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Xencor by 12.3% in the fourth quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company's stock valued at $37,578,000 after acquiring an additional 179,526 shares during the period.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. William Blair assumed coverage on Xencor in a report on Monday, April 21st. They issued an "outperform" rating for the company. Barclays decreased their price objective on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. StockNews.com downgraded Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Wells Fargo & Company lowered their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, Wedbush reissued an "outperform" rating and set a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. Two equities research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Xencor presently has an average rating of "Moderate Buy" and a consensus price target of $29.50.

Xencor Stock Performance

NASDAQ:XNCR remained flat at $8.06 during trading hours on Monday. The company's stock had a trading volume of 728,954 shares, compared to its average volume of 646,631. The company has a 50-day moving average price of $10.08 and a 200-day moving average price of $17.06. The firm has a market capitalization of $573.64 million, a P/E ratio of -2.52 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a 1 year low of $7.16 and a 1 year high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The business had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company's revenue was up 104.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.11) EPS. As a group, analysts predict that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Nancy Valente sold 4,616 shares of Xencor stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the transaction, the executive vice president now owns 49,169 shares of the company's stock, valued at $542,334.07. The trade was a 8.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.76% of the stock is currently owned by company insiders.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.